{"id":"https://openalex.org/W4303473128","doi":"https://doi.org/10.1111/bcp.15548","title":"Spotlight commentary: Navigating between financial risks and improved treatment outcomes with immune checkpoint inhibitors in cancer patients: The need for biomarker identification and dose optimization","display_name":"Spotlight commentary: Navigating between financial risks and improved treatment outcomes with immune checkpoint inhibitors in cancer patients: The need for biomarker identification and dose optimization","publication_year":2022,"publication_date":"2022-10-07","ids":{"openalex":"https://openalex.org/W4303473128","doi":"https://doi.org/10.1111/bcp.15548","pmid":"https://pubmed.ncbi.nlm.nih.gov/36206769"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.15548","doi":"https://doi.org/10.1111/bcp.15548","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bcp.15548","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"editorial","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065495586","display_name":"Robert Liki\u0107","orcid":"https://orcid.org/0000-0003-1413-4862","observed_orcids":["https://orcid.org/0000-0003-1413-4862"]},"institutions":[{"id":"https://openalex.org/I138937732","display_name":"University Hospital Centre Zagreb","ror":"https://ror.org/00r9vb833","country_code":"HR","type":"healthcare","lineage":["https://openalex.org/I138937732"]},{"id":"https://openalex.org/I181343428","display_name":"University of Zagreb","ror":"https://ror.org/00mv6sv71","country_code":"HR","type":"education","lineage":["https://openalex.org/I181343428"]}],"countries":["HR"],"is_corresponding":true,"raw_author_name":"Robert Likic","raw_affiliation_strings":["Department of Internal Medicine, Division of Clinical Pharmacology and Therapeutics, Clinical Hospital Centre Zagreb, Zagreb, Croatia","University of Zagreb Medical School, Zagreb, Croatia"],"raw_orcid":"https://orcid.org/0000-0003-1413-4862","affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Division of Clinical Pharmacology and Therapeutics, Clinical Hospital Centre Zagreb, Zagreb, Croatia","institution_ids":["https://openalex.org/I138937732"]},{"raw_affiliation_string":"University of Zagreb Medical School, Zagreb, Croatia","institution_ids":["https://openalex.org/I181343428"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081027585","display_name":"James W. Dear","orcid":"https://orcid.org/0000-0002-8630-8625","observed_orcids":["https://orcid.org/0000-0002-8630-8625"]},"institutions":[{"id":"https://openalex.org/I4210164624","display_name":"The Queen's Medical Research Institute","ror":"https://ror.org/059zxg644","country_code":"GB","type":"government","lineage":["https://openalex.org/I4210164624","https://openalex.org/I98677209"]},{"id":"https://openalex.org/I98677209","display_name":"University of Edinburgh","ror":"https://ror.org/01nrxwf90","country_code":"GB","type":"education","lineage":["https://openalex.org/I98677209"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"James W. Dear","raw_affiliation_strings":["Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK"],"raw_orcid":"https://orcid.org/0000-0002-8630-8625","affiliations":[{"raw_affiliation_string":"Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK","institution_ids":["https://openalex.org/I4210164624","https://openalex.org/I98677209"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080500055","display_name":"Lionel D. Lewis","orcid":"https://orcid.org/0000-0003-1164-5157","observed_orcids":["https://orcid.org/0000-0003-1164-5157"]},"institutions":[{"id":"https://openalex.org/I1289422878","display_name":"Dartmouth\u2013Hitchcock Medical Center","ror":"https://ror.org/00d1dhh09","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I107672454","https://openalex.org/I1289422878","https://openalex.org/I4390039337"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lionel D. Lewis","raw_affiliation_strings":["Section of Clinical Pharmacology, Dept. of Medicine The Geisel School of Medicine &amp; Dartmouth\u2010Hitchcock Medical Centre  Lebanon New Hampshire USA","Section of Clinical Pharmacology, Dept. of Medicine, The Geisel School of Medicine & Dartmouth-Hitchcock Medical Centre, Lebanon, New Hampshire, USA"],"raw_orcid":"https://orcid.org/0000-0003-1164-5157","affiliations":[{"raw_affiliation_string":"Section of Clinical Pharmacology, Dept. of Medicine The Geisel School of Medicine &amp; Dartmouth\u2010Hitchcock Medical Centre  Lebanon New Hampshire USA","institution_ids":["https://openalex.org/I1289422878"]},{"raw_affiliation_string":"Section of Clinical Pharmacology, Dept. of Medicine, The Geisel School of Medicine & Dartmouth-Hitchcock Medical Centre, Lebanon, New Hampshire, USA","institution_ids":["https://openalex.org/I1289422878"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5065495586"],"corresponding_institution_ids":["https://openalex.org/I138937732","https://openalex.org/I181343428"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"88","issue":"12","first_page":"5060","last_page":"5063"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.859000027179718},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.6830000281333923},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.9760000109672546},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.8489999771118164},{"id":"https://openalex.org/keywords/pd-1-pd-l1","display_name":"PD-1/PD-L1","score":0.8659999966621399},{"id":"https://openalex.org/keywords/t-cell-activation","display_name":"T cell activation","score":0.5830000042915344},{"id":"https://openalex.org/keywords/immunotherapy-safety","display_name":"immunotherapy safety","score":0.5540000200271606},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.574999988079071},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.6800000071525574},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.6899999976158142},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.7049999833106995},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.49300000071525574},{"id":"https://openalex.org/keywords/vitiligo","display_name":"vitiligo","score":0.718999981880188},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.44699999690055847},{"id":"https://openalex.org/keywords/treatment-outcomes","display_name":"treatment outcomes","score":0.31700000166893005},{"id":"https://openalex.org/keywords/financial-risk","display_name":"financial risk","score":0.3799999952316284},{"id":"https://openalex.org/keywords/regulatory-approval","display_name":"regulatory approval","score":0.47999998927116394}],"concepts":[{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6802292466163635},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5795142650604248},{"id":"https://openalex.org/C116834253","wikidata":"https://www.wikidata.org/wiki/Q2039217","display_name":"Identification (biology)","level":2,"score":0.5425111055374146},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5087526440620422},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5011799335479736},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4333066940307617},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.12878140807151794},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09330210089683533},{"id":"https://openalex.org/C59822182","wikidata":"https://www.wikidata.org/wiki/Q441","display_name":"Botany","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/bcp.15548","doi":"https://doi.org/10.1111/bcp.15548","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bcp.15548","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:36206769","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36206769","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[{"id":"https://openalex.org/G9000859653","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA023108","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W1950972410","https://openalex.org/W2263759961","https://openalex.org/W2567068937","https://openalex.org/W2747792808","https://openalex.org/W2947160942","https://openalex.org/W3015319828","https://openalex.org/W3017599093","https://openalex.org/W3021452266","https://openalex.org/W3027513095","https://openalex.org/W3029125180","https://openalex.org/W3098006375","https://openalex.org/W4220913099","https://openalex.org/W6922416790"],"related_works":["https://openalex.org/W2977567396","https://openalex.org/W4315631827","https://openalex.org/W2947849947","https://openalex.org/W4407186436","https://openalex.org/W2984538501","https://openalex.org/W4396680436","https://openalex.org/W2590829109","https://openalex.org/W4226157257","https://openalex.org/W3029129345","https://openalex.org/W4417163350"],"abstract_inverted_index":{"Modulation":[0],"of":[1,24,33,92,109,130,204,214,268,276,328,394,404,469,536,542,636,688,828,856,886,910,933,986,1024,1045,1065,1069,1086,1095,1117,1148,1176,1185,1193,1263,1268,1298,1380,1388,1427,1508,1516],"the":[2,21,28,34,84,90,107,110,115,128,131,266,301,304,323,337,358,365,379,392,402,436,445,470,614,631,680,684,779,806,812,826,843,853,857,862,953,983,1003,1007,1017,1063,1066,1073,1076,1087,1115,1127,1132,1149,1167,1171,1191,1227,1255,1259,1296,1408,1449,1484,1490,1527,1532,1539,1549],"immune":[3,332,588,628],"system":[4,1452],"to":[5,12,42,53,69,95,114,133,149,179,188,192,199,238,331,364,378,396,413,451,461,498,505,534,566,621,682,702,718,756,764,796,811,961,1002,1005,1010,1022,1030,1052,1102,1123,1200,1220,1236,1257,1320,1479,1493,1538],"achieve":[6],"a":[7,201,240,249,326,483,585,607,645,708,962,975,1092,1098,1208,1247,1273,1289,1302,1309,1432,1545],"molecular":[8,72],"target":[9,81,442,799],"directed":[10,182],"response":[11,589,629,648],"kill":[13],"cancer":[14,25,44,51,93,156,163,877,969,980,1128,1465],"cells":[15,94,157],"has":[16,262],"always":[17],"been":[18,265,317,901,1050,1180],"considered":[19,973],"as":[20,273,336,559,561,580,690,692,847,917,919,947,974,1036,1061,1106,1215,1330],"holy":[22],"grail":[23],"therapeutics.":[26,981],"Over":[27],"past":[29],"two":[30,1163],"decades,":[31],"many":[32,1341],"global":[35],"regulatory":[36],"agencies":[37],"have":[38,231,316,707,900,989,1019,1049,1179,1530],"approved":[39,360,472,1228,1531],"several":[40,318,593],"immunotherapies":[41],"treat":[43],"patients,":[45,970,993],"ranging":[46],"from":[47,489,861,1057,1489,1548],"oncolytic":[48],"viruses":[49],"and":[50,59,151,164,209,279,289,341,346,383,443,455,457,465,515,526,602,630,638,686,704,722,748,784,801,819,834,840,892,914,999,1142,1170,1211,1265,1270,1305,1349,1417,1444,1453,1456,1472,1503,1529],"vaccines":[52],"chimeric":[54,62],"antigen":[55,122],"receptor":[56,112,370,410],"(CAR)":[57],"T-cells":[58,101],"human":[60,887],"or":[61,126,233,242,421,657,1119],"monoclonal":[63],"antibodies":[64],"(mAbs)":[65],"that":[66,80,146,212,229,307,362,441,449,459,548,617,695,741,836,928,1075,1160,1245,1323,1339,1535],"bind":[67,450,460],"specifically":[68],"cell":[70,124,162,166,184,406,417,423],"surface":[71],"targets.":[73],"Immune":[74],"checkpoint":[75,333],"inhibitors":[76,334,706],"(ICIs)":[77],"are":[78,102,143,197,430,477,939,972,1318,1477,1505,1542],"mAbs":[79],"molecules":[82],"in":[83,255,271,283,295,322,352,479,544,564,650,673,711,736,745,805,876,923,937,955,979,1062,1084,1114,1131,1139,1153,1155,1161,1197,1327,1340,1366,1382,1407,1459,1474,1482,1498,1523],"T-cell":[85,98,111,153,181,385],"activation":[86],"pathway,":[87],"thereby":[88],"impairing":[89],"ability":[91],"suppress":[96],"cytotoxic":[97,194,366,586],"antitumour":[99,627],"activity.":[100],"typically":[103,263],"activated":[104],"either":[105],"by":[106,435,610,904,1253,1346,1500],"binding":[108,129,393,403],"(TCR)":[113],"major":[116,976],"histocompatibility":[117],"complex":[118],"(MHC)":[119],"on":[120,136,372,381,411,427,597,782,790,830,872],"an":[121,137,581,625,1513],"presenting":[123],"(APC)":[125],"through":[127,391],"CD28":[132,395],"CD80/CD86":[134],"(B7)":[135],"APC,":[138,382],"Figure":[139],"1.":[140,481],"Additionally,":[141],"there":[142,1384],"inhibitory":[144,174],"pathways":[145],"physiologically":[147],"function":[148],"downregulate":[150],"control":[152],"responses.":[154],"Certain":[155],"(for":[158],"example":[159],"melanoma,":[160],"renal":[161],"non-small":[165],"lung":[167],"cancer)":[168],"express":[169],"receptors":[170],"specific":[171,753],"for":[172,253,303,474,624,668,792,816,852,944,964,1041,1145,1225,1312,1332,1359,1378,1424,1448,1464,1487],"these":[173,215,475,817,987,1011,1162],"pathways,":[175],"which":[176,348,375,387,1421],"enable":[177],"them":[178],"evade":[180],"anti-cancer":[183],"cytotoxicity.1":[185],"In":[186,482,606,772,1300,1364],"contrast":[187],"adverse":[189,206,494,521,1173,1347,1442],"events":[190,207,522,1348,1443],"related":[191,504,533],"classical":[193],"chemotherapy,":[195],"ICIs":[196,254,309,433,476,543,971,1037,1143],"known":[198],"cause":[200],"broad":[202],"spectrum":[203],"immune-related":[205],"(irAEs)":[208],"it":[210,274,1158,1241],"seems":[211],"some":[213],"AEs":[216],"might":[217],"be":[218,227,622,644,677,1188,1243,1251,1286,1308,1325,1395],"associated":[219,509,552],"with":[220,236,297,312,510,553,590,655,751,768,809,868,1013,1097,1223,1371,1414],"non-optimized":[221],"treatment":[222,634,699,1333,1379,1462],"regimens.":[223],"It":[224],"would":[225,388,762,1422,1439],"not":[226,264,665,1250,1362],"unusual":[228],"sponsors":[230,1216],"planned":[232],"even":[234,943,1398],"agreed":[235,1294],"regulators":[237,1186],"run":[239],"fast-track":[241],"conditional":[243],"approval":[244,1068,1206],"programmes":[245],"after":[246,1204],"having":[247],"identified":[248],"strong":[250,1274],"efficacy":[251,311],"signal":[252],"early":[256],"clinical":[257,269,1328],"trials.":[258],"Moreover,":[259],"dose":[260,342,693,813,1195,1275,1313],"optimization":[261],"focus":[267],"research":[270,672],"oncology":[272],"is":[275,287,291,664,1207,1344,1361,1385,1496,1512],"secondary":[277],"importance":[278],"often":[280,532,1212,1218],"completely":[281],"overlooked":[282],"areas":[284],"where":[285,1280],"prognosis":[286],"poor,":[288],"survival":[290,558,563,967,1082,1360],"short.":[292],"Clinical":[293],"pharmacologists":[294],"conjunction":[296],"oncologists":[298],"must":[299],"continue":[300],"search":[302],"optimal":[305,798],"biomarker(s)":[306],"predicts":[308],"therapeutic":[310,770],"minimal":[313],"toxicity.":[314],"There":[315,429],"recent":[319,484,773,925,1140],"papers":[320],"published":[321],"Journal":[324],"covering":[325],"range":[327,1056],"issues":[329],"relating":[330],"such":[335,1035,1105,1246,1301,1400],"safety":[338],"profile,":[339],"PK":[340,746,794,832,864,874],"modelling,":[343],"mechanisms,":[344],"vitiligo,":[345,569],"cost-effectiveness,":[347],"we":[349],"will":[350,1217,1394,1404],"highlight":[351],"this":[353,618,674,1202,1475],"Spotlight":[354],"commentary.":[355],"Ipilimumab":[356],"was":[357,550,1536],"first":[359],"mAb":[361,712],"binds":[363,377],"T-lymphocyte":[367,587],"antigen-4":[368],"(CTLA-4)":[369],"found":[371],"T":[373],"lymphocytes,":[374],"normally":[376,389],"B7":[380],"blocks":[384],"activation,":[386],"occur":[390],"B7.":[397],"Another":[398],"inhibitory/immunosuppressive":[399],"pathway":[400],"involves":[401],"programmed":[405,416,422],"death":[407],"protein-1":[408],"(PD-1)":[409],"T-lymphocytes":[412],"its":[414,1137],"ligands:":[415],"death-ligand":[418,424],"1":[419],"(PD-L1)":[420],"2":[425,1357],"(PD-L2)":[426],"APCs.":[428],"currently":[431,471],"six":[432],"approved/registered":[434],"FDA,":[437],"MHRA":[438],"and/or":[439],"EMA":[440],"block":[444],"PD-1/PD-L1":[446],"pathway:":[447],"three":[448,458,1519],"PD-1:":[452],"cemiplimab-rwic,":[453],"nivolumab":[454,783],"pembrolizumab":[456,656],"PD-L1:":[462],"avelumab,":[463],"atezolizumab":[464],"durvalumab.":[466],"The":[467,895,1183],"details":[468],"indications":[473],"shown":[478],"Table":[480],"study,":[485],"Cutroneo":[486],"et":[487,612,734,776,786,823,1125],"al.2":[488],"Italy":[490],"evaluated":[491],"302":[492],"196":[493],"drug":[495,661,766,898,911,948,1129,1205,1428],"reports":[496],"pertaining":[497],"antineoplastic":[499],"agents,":[500],"2217":[501],"(0.7%)":[502],"were":[503,530,842,850],"ICIs,":[506],"IrAEs":[507],"commonly":[508],"ipilimumab":[511,791],"involved":[512],"colitis":[513],"(45.3%),":[514],"skin":[516],"disorders":[517],"(22.6%),":[518],"while":[519,1510],"musculoskeletal":[520],"(8.5%),":[523],"respiratory":[524],"(18.8%)":[525],"endocrine":[527],"dysfunction":[528],"(18.7%)":[529],"more":[531],"use":[535,1023,1354],"other":[537,640,658,820],"anti-PD-1/PD-L1":[538],"agents.":[539],"A":[540,1043],"meta-analysis":[541],"melanoma":[545,604,652],"patients":[546,567,653,878,1096,1232,1455,1466],"demonstrated":[547,835],"vitiligo":[549,637],"significantly":[551],"both":[554,596],"improved":[555,1435],"progression":[556],"free":[557],"well":[560,691,918,1181],"overall":[562,1460],"comparison":[565],"without":[568],"HR":[570],"0.51,":[571],"95%":[572],"CI":[573],"(0.32\u20130.82;":[574],"p":[575],"<":[576],".005).3":[577],"Pembrolizumab":[578],"(acting":[579],"Anti-PD-1":[582],"agent)":[583],"induces":[584],"cross-reactivity":[591,619],"against":[592],"antigens":[594],"expressed":[595],"non-malignant":[598],"melanocytes":[599],"(MART-1,":[600],"tyrosinase)":[601],"malignant":[603,651],"cells.":[605],"case":[608,1064],"report":[609],"Bulat":[611],"al.,4":[613],"authors":[615,1520],"suggest":[616],"appears":[620],"predictive":[623],"enhanced":[626],"post":[632],"ICI":[633,1177,1374,1390],"development":[635,885],"potentially":[639,697,869,1440],"cutaneous":[641],"irAEs":[642,689],"could":[643,1324],"positive":[646],"prognostic":[647],"biomarker":[649],"treated":[654],"ICIs.":[659,1468],"Therapeutic":[660],"monitoring":[662],"(TDM)":[663],"routinely":[666],"undertaken":[667],"ICIs;":[669],"however,":[670],"further":[671],"field":[675],"may":[676],"warranted,":[678],"considering":[679],"potential":[681,1172],"reduce":[683,698,1441],"severity":[685],"duration":[687],"modification":[694],"can":[696,1307],"costs.":[700],"Responders":[701],"PD-1":[703],"PD-L1":[705],"significant":[709],"decrease":[710],"clearance":[713,754,1391],"over":[714,1392],"time,":[715,1393],"likely":[716,728,1430,1457],"due":[717,1001],"reduced":[719],"disease":[720],"burden,":[721],"thus":[723],"current":[724],"standard":[725,932],"dosing":[726,760,1110,1375,1402],"regimens":[727,1279,1403],"produce":[729],"supratherapeutic":[730],"serum":[731],"concentrations.":[732],"Peer":[733],"al.5":[735],"their":[737,848,1014],"review":[738],"article":[739,1476],"suggested":[740],"using":[742],"Bayesian":[743],"methods":[744,1029],"modelling":[747,795,1304],"simulation":[749,1306],"together":[750],"patient":[752,807],"estimates":[755],"generate":[757],"personalized":[758,1278],"alternative":[759],"strategies":[761],"lead":[763],"lower":[765],"expenditure":[767],"retained":[769],"efficacy.":[771],"studies,":[774],"Bajaj":[775,822],"al.6":[777],"used":[778,788,815,1326],"available":[780,1543],"data":[781,789,1083,1089,1488],"Feng":[785],"al.7":[787],"population":[793,808,831],"assess":[797,1031],"exposure":[800],"unaccounted":[802],"interindividual":[803,859],"differences":[804],"regards":[810],"rationale":[814],"drugs":[818,988,1012],"mAbs.":[821],"al.8":[824],"compared":[825],"effects":[827,849,871],"covariates":[829,867],"parameters":[833],"body":[837],"weight,":[838],"albumin":[839],"sex":[841],"most":[844],"relevant":[845],"ones,":[846],"responsible":[851],"highest":[854],"proportion":[855],"unexplained":[858],"variability":[860,875,1269],"base":[863],"parameters.":[865],"Other":[866],"additional":[870,1081],"mAbs'":[873],"included":[879],"tumour":[880],"type,":[881],"ECOG":[882],"performance":[883],"status,":[884],"anti-ICI":[888],"antibodies,":[889],"estimated":[890],"GFR":[891],"creatinine":[893],"clearance.8":[894],"globally":[896],"rising":[897],"prices":[899],"brought":[902],"forth":[903],"patent":[905],"established":[906],"monopolies,":[907],"unanticipated":[908],"consequences":[909],"registration":[912],"laws":[913],"reimbursement":[915,1071,1168],"policies":[916],"market":[920],"forces.9":[921],"Likic,10":[922],"his":[924],"editorial,":[926],"proposed":[927],"modern":[929],"health":[930,994,997,1025,1450],"care":[931,934,995,1451],"practices,":[935],"particularly":[936,1377],"oncology,":[938],"gradually":[940],"becoming":[941],"unaffordable,":[942],"developed":[945],"countries,":[946],"costs":[949,985],"increases":[950],"percentwise":[951],"outpace":[952],"rise":[954],"national":[956],"gross":[957],"domestic":[958],"products.":[959],"Owing":[960],"possibility":[963],"long":[965,1352],"term":[966,1353],"among":[968,992],"paradigm":[977,1438],"shift":[978],"However,":[982,1240],"initial":[984,1088],"caused":[990],"concern":[991],"providers,":[996],"insurers":[998],"researchers,":[1000],"need":[1004,1256,1405],"balance":[1006],"equitable":[1008],"access":[1009,1235],"affordability.":[1015,1054],"Consequently,":[1016],"payers":[1018],"ubiquitously":[1020],"resorted":[1021],"technology":[1026],"assessment":[1027],"(HTA)":[1028],"if":[1032,1336],"novel":[1033],"therapies,":[1034],"provide":[1038],"good":[1039],"value":[1040],"money.":[1042],"number":[1044,1094],"managed":[1046],"entry":[1047],"schemes":[1048,1104],"devised":[1051],"improve":[1053],"These":[1055],"outcome":[1058,1415],"based":[1059,1368,1416],"schemes,":[1060],"NICE's":[1067],"avelumab":[1070],"under":[1072],"condition":[1074],"marketing":[1077],"authorization":[1078],"holder":[1079],"supplies":[1080],"light":[1085],"set":[1090],"containing":[1091],"small":[1093],"short":[1099],"follow":[1100],"up11;":[1101],"non-outcome-based":[1103],"price":[1107],"volume":[1108],"agreements,":[1109],"caps,":[1111],"discounts":[1112],"(usually":[1113],"form":[1116],"rebates)":[1118],"hypothecated":[1120],"budgets.":[1121],"According":[1122],"Kim":[1124],"al.,12":[1126],"fund":[1130],"United":[1133],"Kingdom":[1134],"stayed":[1135],"within":[1136],"budget":[1138,1152],"years":[1141],"accounted":[1144],"only":[1146],"5%":[1147],"total":[1150],"medicines":[1151],"2019":[1154],"Australia.":[1156],"Therefore":[1157],"seems,":[1159],"countries":[1164],"at":[1165,1295],"least,":[1166],"policy":[1169],"financial":[1174],"impact":[1175],"therapy":[1178],"managed.":[1182],"attention":[1184],"should":[1187,1242,1249,1284],"drawn":[1189],"towards":[1190,1434],"problem":[1192,1203],"poor":[1194],"finding":[1196],"oncology.":[1198],"Trying":[1199],"fix":[1201],"complex,":[1209],"resource-intensive,":[1210],"counterproductive":[1213],"task,":[1214],"try":[1219],"come":[1221],"up":[1222],"arguments":[1224],"keeping":[1226],"label":[1229],"recommendations.":[1230],"Oncology":[1231],"deserve":[1233],"fast":[1234],"novel,":[1237],"innovative":[1238],"drugs.":[1239],"clear":[1244],"strategy":[1248],"implemented":[1252],"waving":[1254],"establish":[1258],"exposure-response":[1260],"relationship,":[1261],"identification":[1262],"intrinsic":[1264],"extrinsic":[1266],"sources":[1267],"consequently":[1271],"providing":[1272],"rationale,":[1276],"i.e.,":[1277],"appropriate.":[1281],"This":[1282,1410,1437],"requirement":[1283],"ideally":[1285],"translated":[1287],"into":[1288],"phase":[1290],"IV":[1291],"trial":[1292],"commitment":[1293],"time":[1297],"approval.":[1299],"scenario,":[1303],"robust":[1310],"tool":[1311],"optimization.":[1314],"Furthermore,":[1315],"joint":[1316],"efforts":[1317],"needed":[1319],"identify":[1321],"biomarkers":[1322],"practice":[1329],"guidance":[1331],"cessation,":[1334],"specially":[1335],"one":[1337],"considers":[1338],"cases":[1342],"cessation":[1343],"determined":[1345],"evidence":[1350,1387],"supporting":[1351],"(more":[1355],"than":[1356],"years)":[1358],"definitive.13":[1363],"conclusion,":[1365],"silico":[1367],"pharmacokinetic":[1369],"simulations":[1370],"extended":[1372],"interval":[1373],"regimens,":[1376],"responders,":[1381],"whom":[1383],"substantial":[1386],"decreasing":[1389],"increasingly":[1396],"utilized,":[1397],"though":[1399],"modelled":[1401],"confirmation":[1406],"clinic.":[1409],"approach":[1411],"when":[1412],"combined":[1413],"pay-for-performance":[1418],"pricing":[1419],"policies,":[1420],"allow":[1423],"ongoing":[1425],"renegotiation":[1426],"prices,":[1429],"represents":[1431],"path":[1433],"equity.":[1436],"mitigate":[1445],"\u201cfinancial":[1446],"toxicity,\u201d":[1447],"individual":[1454],"result":[1458],"better":[1461],"outcomes":[1463],"receiving":[1467],"Key":[1469],"protein":[1470],"targets":[1471],"ligands":[1473],"hyperlinked":[1478],"corresponding":[1480],"entries":[1481],"http://www.guidetopharmacology.org,":[1483],"common":[1485],"portal":[1486],"IUPHAR/BPS":[1491],"Guide":[1492],"PHARMACOLOGY.":[1494],"LDL":[1495,1511],"supported":[1497],"part":[1499,1522],"5P30CA023108-43.":[1501],"RL":[1502],"JWD":[1504],"senior":[1506],"editors":[1507],"BJCP,":[1509],"executive":[1514],"editor":[1515],"BJCP.":[1517],"All":[1518],"took":[1521],"writing,":[1524],"critically":[1525],"revising":[1526],"manuscript":[1528],"final":[1533],"version":[1534],"submitted":[1537],"journal.":[1540],"Data":[1541],"upon":[1544],"reasonable":[1546],"request":[1547],"authors.":[1550]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2022-10-08T00:00:00"}